Levetiracetam Aurobindo

Levetiracetam, the active ingredient in Levetiracetam Aurobindo, is an antiepileptic presented as an oral tablet for oral use and marketed in the European Union. It is indicated for the treatment of partial‑onset, generalized tonic‑clonic and myoclonic seizures in patients diagnosed with epilepsy, helping to reduce seizure frequency and improve neurological stability.

GNH USA supplies Levetiracetam Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with capabilities for bulk manufacturing, quality assurance and regulatory support to meet global market demands.

Levetiracetam is an antiepileptic drug that reduces neuronal hyper‑excitability in various seizure types. - Partial‑onset seizures: reduces frequency of focal seizures and improves seizure control. - Generalized tonic‑clonic seizures: helps prevent convulsive episodes in patients with generalized epilepsy. - Myoclonic seizures: decreases rapid muscle jerks associated with myoclonic epilepsy.

Levetiracetam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness - Fatigue - Headache - Somnolence - Irritability

Serious or Rare Side Effects: - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Depression or suicidal thoughts - Blood dyscrasias (e.g., neutropenia, thrombocytopenia) - Hepatic dysfunction

When prescribing levetiracetam, clinicians should consider several safety aspects. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes periodically. - Psychiatric symptoms: observe for mood changes, depression, or suicidal ideation. - Pregnancy: risk category unknown; discuss potential benefits and risks with the patient. - Concomitant CNS depressants: use caution as additive sedation may occur. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Levetiracetam can interact with other medicines, influencing its plasma levels or enhancing central nervous system effects.

Major Interactions (Avoid): - Carbamazepine: may significantly reduce levetiracetam concentrations. - Phenytoin: may lower levetiracetam exposure. - Phenobarbital: can decrease levetiracetam levels.

Moderate Interactions (Monitor Closely): - Benzodiazepines: may increase sedation when combined. - Alcohol: can enhance central nervous system depression. - Antidepressants: monitor for worsening mood or suicidal thoughts.